ArticleBMC public health2025
Burden and inequality of autism spectrum disorders in global, East asian, and Southeast Asian regions, 1990-2021: result from the global burden of disease study 2021.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Analysis of the global burden, biological risk factors, and implications of autism spectrum disorder.Pediatric research · 2026Article
- Prevalence and age of diagnosis of neurodevelopmental conditions among Asian populations in Aotearoa New Zealand.Journal of neurodevelopmental disorders · 2026Article
- Sports and physical activity interventions in autism spectrum disorder: a systematic literature review and meta-analysis.Frontiers in sports and active living · 2026Article
- Autism spectrum disorder in Saudi Arabia: Clinical dynamics from a multi-center study.Saudi medical journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionAutism Spectrum Disorders (ASD) represent a range of neurodevelopmental conditions characterized by abnormal behavioral patterns. ASD is frequently comorbid with other neurodevelopmental disorders. However, there remains a gap in research on the burden of ASD in East and Southeast Asia.
methodsWe stratified the analysis by region, country, age, and sex; used the Sociodemographic Index (SDI) as a pivot to examine the relationship between the burden of autism and SDI through frontier analysis and health inequality analysis; and finally projected global, sex-specific trends in ASD disease burden from 2022 to 2050.
resultThe global burden of ASD, including in East and Southeast Asia, has exhibited a generally increasing trend over recent decades. Japan demonstrated a relatively high ASD burden. The analysis revealed that females tend to experience a higher burden than males, and ASD is more prevalent among younger age groups. A positive correlation was observed between SDI and ASD burden, with higher SDI levels associated with greater burden. Health inequality analyses indicated that while ASD prevalence and Years Lived with Disability (YLDs) are predominantly concentrated in high-SDI countries, incidence rates are higher in low-SDI regions. Finally, the global burden of ASD among both males and females is projected to continue rising through the year 2050.
conclusionThe burden of ASD in East and Southeast Asia continues to increase year by year. High-SDI countries tend to report a greater disease burden. From 1990 to 2021, nearly all countries in the region experienced a continuous rise in ASD burden. Although there is a growing trend of ASD incidence shifting toward low-SDI countries, prevalence and years lived with disability (YLDs) remain predominantly concentrated in high-SDI countries. Finally, the global burden of ASD among both males and females is projected to continue rising through 2050.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.